Zaremba T, Gierschik P, Pines M, Bray P, Carter A, Kahn R, Simons C, Vinitsky R, Goldsmith P, Spiegel A
Molecular Pathophysiology Section, National Institute of Diabetes, Digestive, and Kidney Disease, Bethesda, Maryland 20892.
Mol Pharmacol. 1988 Mar;33(3):257-64.
Twenty-four of 24 rabbits immunized with the beta subunit common to guanine nucleotide binding proteins developed antibodies reactive on immunoblots with the 15-kDa (amino-terminal) tryptic fragment of beta. Only 2 of 24 developed antibodies reactive with the 26-kDa (carboxy-terminal) tryptic fragment. The 15-kDa fragment-reactive antibodies were also detected in several nonimmune sera. Antibodies reactive with the 15-kDa fragment could be affinity-purified from all beta-immune sera by adsorption to a fusion protein encoded by a cDNA clone identified by expression vector screening. The 15-kDa fragment antibodies in nonimmune sera did not bind to the fusion protein. Limited amino acid sequence homology between the 36-kDa beta subunit and the protein encoded by the cDNA clone suggested that the amino-terminal decapeptide of beta contains a major epitope. A synthetic decapeptide, corresponding to the amino terminus of the 36-kDa beta subunit, effectively and specifically blocked binding of antibodies in beta-immune sera (but not in beta-reactive nonimmune sera) to nitrocellulose-bound 15-kDa fragment. The 15-kDa fragment-reactive antibodies could be affinity-purified from beta-immune sera on a matrix containing bound decapeptide; affinity-purified antibodies reacted equally well with the 36- and 35-kDa forms of the beta subunit. Native transducin beta/gamma complexes readily blocked binding of 15-kDa fragment-reactive antibodies in immune but not nonimmune sera from binding to the nitrocellulose-bound fragment. The results show that nonimmune sera may contain antibodies directed against an epitope of the 15-kDa fragment that is buried in the native beta/gamma complex. In contrast, the amino terminal decapeptide of the beta subunit is exposed on the surface of the native protein and contains a major antigenic site in both the 35- and 36-kDa forms.
用鸟嘌呤核苷酸结合蛋白的β亚基共同部分免疫的24只兔子中,有24只产生了与β亚基15 kDa(氨基末端)胰蛋白酶片段在免疫印迹上发生反应的抗体。24只中只有2只产生了与26 kDa(羧基末端)胰蛋白酶片段发生反应的抗体。在几份非免疫血清中也检测到了与15 kDa片段发生反应的抗体。与15 kDa片段发生反应的抗体可通过吸附到由表达载体筛选鉴定的cDNA克隆编码的融合蛋白上,从所有β免疫血清中进行亲和纯化。非免疫血清中的15 kDa片段抗体不与融合蛋白结合。36 kDaβ亚基与cDNA克隆编码的蛋白之间有限的氨基酸序列同源性表明,β亚基的氨基末端十肽含有一个主要表位。一种与36 kDaβ亚基氨基末端相对应的合成十肽有效地且特异性地阻断了β免疫血清(而非β反应性非免疫血清)中的抗体与硝酸纤维素结合的15 kDa片段的结合。与15 kDa片段发生反应的抗体可在含有结合十肽的基质上从β免疫血清中进行亲和纯化;亲和纯化的抗体与36 kDa和35 kDa形式的β亚基反应同样良好。天然转导素β/γ复合物很容易阻断免疫血清(而非非免疫血清)中与15 kDa片段发生反应的抗体与硝酸纤维素结合片段的结合。结果表明,非免疫血清可能含有针对15 kDa片段中一个表位的抗体,该表位在天然β/γ复合物中是被掩埋的。相比之下,β亚基的氨基末端十肽暴露在天然蛋白表面,并且在35 kDa和36 kDa形式中都含有一个主要抗原位点。